The characteristics of the patients who were more likely to benefit from SGLT2i or GLP-1 RA were mostly balanced between patients who received SGLT2i or GLP-1 RA and those who did not, except for the number of female patients and the presence of dyslipidemia, retinopathy, and neuropathy, which were significantly higher among patients who were preferably prescribed SGLT2i or GLP-1 RA, as shown in Table 3. The gene discussed is GLP1R; the disease is neuropathy.